Conclusion
NSCLC
NSCLC
Toripalimab combined with anlotinib was tolerable in EGFR‐TKI‐resistant advanced NSCLC patients not previously treated with chemotherapy. Patients without detectable 
Shuyang Zhang and Lu Yang contributed equally to this work.